Spots Global Cancer Trial Database for NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Official Title: NEO-adjuvant Chemo-Immunotherapy in Pancreatic Cancer
Study ID: NCT06094140
Conditions
Study Description
Brief Summary: To determine the safety and tolerability of adding durvalumab to mFOLFIRINOX prior to surgery in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Detailed Description: Despite curative surgery, pancreatic cancer patients have five-year survival rates of 20%. Adjuvant chemotherapy has improved survival in resected pancreatic cancer patients but only 10-15% are suitable for surgery and 30% of the resected pancreatic cancer patients miss out on adjuvant chemotherapy due to postoperative complications. Neoadjuvant chemotherapy has improved the resection rates in the patients with non-metastatic pancreatic cancer. There is a growing interest to combine chemotherapy with checkpoint inhibitors to improve disease control in the early stage of pancreas cancer. The investigators propose a pilot study to evaluate the feasibility and safety of combining modified FOLFIRINOX (mFOLFIRINOX) with durvalumab (MEDI4736) in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GenesisCare North Shore, Sydney, New South Wales, Australia
Wollongong Hospital, Wollongong, New South Wales, Australia
Warringal Private Hospital, Melbourne, Victoria, Australia
Contact Details
Name: Lorraine Chantrill, Professor
Affiliation: AGITG
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
